2019

September 9

Specific Diagnostics Announces that Eric B. Stang Joins Its Advisory Board

Specific Diagnostics is very pleased to announce that Eric B. Stang has joined Specific’s Advisory Board. Mr. Stang is an experienced public company CEO and Board Member, currently CEO and Chairman of OOMA (NYSE), as well as member of the Board of Directors of Rambus (NASDAQ)

September 6

Specific Diagnostics Receives Investment from Telegraph Hill Partners to Commercialize Critical Drug Susceptibility Technology for Clinical Microbiology Labs

Specific Diagnostics today announced an investment of $12.5M by Telegraph Hill Partners (THP), a venture capital and growth equity firm focused on building leading life science and healthcare companies. The funding will support the commercialization of Specific’s Reveal™ platform, which will provide a rapid, accurate antibiotic susceptibility test critical to the treatment of deadly drug resistant infections…

August 3

Carb-X to Expand Funding of Specific Diagnostics to Support the Development of a Rapid Antibiotic Susceptibility Test to Treat Life-Threatening Blood Infections

Specific’s Reveal antibiotic susceptibility testing system promises accurate drug susceptibility and identification of superbugs within 5 hours of a positive blood sample, improving patient care in the case life-threatening sepsis, especially in the case of drug resistant blood infections

June 5

Specific Diagnostics Invited to Present at Rapid AST Symposium at IDWeek

Specific Diagnostics has been invited to present its Reveal Rapid AST system at a symposium entitled “Rapid Diagnostics and Resistance: Making Sense of Now and the Future Part 1 – Rapid Phenotypic AST Methods” at IDWeek October 4, in Washington, DC. “Specific welcomes this opportunity to share information about the Reveal instrument which by this time will be in clinical trials in Europe,” said Paul A. Rhodes, Ph.D., Specific Diagnostics CEO.  “We are pleased that the symposium committee extended this invitation.”

March 29

Specific Diagnostics begins clinical demonstrations and testing of the Reveal AST system

Specific Diagnostics today announced clinical demonstrations of the Reveal AST system will be conducted at a clinical laboratory in Amsterdam during the ECCMID conference April 13-16.  The Reveal AST™ system delivers phenotypic AST in an average of 4 hours, directly from positive blood culture or isolate dilutions.  The system provides minimum inhibitory concentration (MIC) with wide antimicrobial coverage for bacteria species responsible for bloodstream and other acute infections… 

March 28

Specific Diagnostics achieves CARB-X milestone and advances its Reveal™ rapid antibiotic susceptibility test for life-threatening drug-resistant infections towards clinical testing

Specific Diagnostics announced today that, based on the achievement of development and testing milestones, CARB-X has proceeded with a second stage of funding for Specific’s Revealrapid antibiotic susceptibility test (AST) instrument.  Specific will receive up to $1.7 million, which is on top of the $1.7 million already awarded by CARB-X. The additional $1.7M will enable Specific’s preparation for clinical trials in 2019 of this important new diagnostic system.  The original CARB-X award, announced April 4, 2018, helped support development of the Reveal AST system, which offers the same-day susceptibility results needed to change the way drug-resistant infections are diagnosed and treated 





2018

June 7

Specific Diagnostics Announces that Dr. Ellen Jo Baron has Joined its Scientific Advisory Board

Specific Diagnostics is very pleased to announce that Ellen Jo Baron, Ph.D., D(ABMM), who for the last 8 years has been the Executive Director of Medical Affairs at Cepheid, has joined Specific’s Scientific Advisory Board.  Dr. Baron, among many other accomplishments, is also a Professor Emerita at Stanford, and a past Medical Director of the Clinical Microbiology Laboratory at Stanford.  Having spent much of the last decade communicating the impact of rapid molecular diagnostic assays to hospitals on Cepheid’s behalf, she brings to Specific unique understanding of and perspective regarding the practical needs of customers as antibiotic-resistant bacterial infection poses an increasingly urgent challenge. 

April 20

Specific Diagnostics unveils the Reveal AST/ID™ system at the ECCMID Conference.

The Reveal AST/ID™ system provides phenotypic susceptibility and ID direct from positive blood cultures with traditional microdilution reliability, in hours not days.

Specific Diagnostics, which has developed innovative paradigms for detection, identification (ID) and antibiotic susceptibility testing (AST) of microorganisms announces that at ECCMID today the Company will showcase the Reveal AST/ID™ system which delivers phenotypic AST and ID in an average of 4 hours, directly from positive blood culture. 

April 19

Specific Diagnostics Announces that Professor Susan Sharp, Immediate Past President of the American Society for Microbiology, has Joined its Scientific Advisory Board

Specific Diagnostics is very pleased to announce that Susan Sharp, Ph.D., D(ABMM), immediate past Regional Director for Microbiology and Molecular Infectious Disease Laboratories, Kaiser Permanente, has joined Specific’s Scientific Advisory Board.  Dr. Sharp is also the immediate Past President of the American Society for Microbiology

April 3

CARB-X partners with Specific Diagnostics to support the development of a rapid accurate test to diagnose life-threatening drug-resistant infections in the blood

(BOSTON, MA) – April 3, 2018 - CARB-X is awarding Specific Diagnostics of Mountain View, CA, up to $1.7 million, with the possibility of up to $1.7 million more based on achievement of project milestones, to support the development of the company's antibiotic susceptibility testing (AST) system, which could be a game-changer in the way drug-resistant infections are diagnosed and treated, resulting in lower health costs and fewer deaths.

January 5

Specific Diagnostics Appoints Robin Patel, M.D., Mayo Clinic, to Scientific Advisory Board

Specific Diagnostics (“Specific”) is pleased to announce that Robin Patel, M.D., D(ABMM), chair, Mayo Clinic Division of Clinical Microbiology, Professor of Microbiology and Medicine, and the Elizabeth P. and Robert E. Allen Professor of Individualized Medicine, has been appointed to the company’s Scientific Advisory Board. Dr. Patel, a widely recognized practice leader across microbiology diagnostics, was recently elected president of the American Society for Microbiology.

2017

June 3

Specific Diagnostics announces unprecedented ability to determine MIC and ID within 4 hours of positive blood culture, using a low-cost disposable.

Specific Diagnostics, which has developed a novel paradigm combining the detection and identification (ID) of microorganisms during blood culture, announces today a revolutionary system combining phenotypic AST with ID, performed in 4 hours directly from a positive blood culture sample.  This capability is revealed in a late-breaker abstract accepted by the American Society for Microbiology to be showcased at the ASM Microbe conference. The abstract will be presented on June 3rd at 12:15 – 2:15, on poster number CPHM LB1.

March 15

Specific Diagnostics announces the combined faster detection and ID of yeast infection in blood culture

Specific Diagnostics, which has developed SpecID™, an innovative paradigm for detection and identification of pathogenic microorganisms based on their volatile metabolic signatures, announces today the publication of a study in PLOS ONE detailing the demonstration of the SpecID™ system to detect and identify pathogenic yeasts in simulated blood culture.

March 2

Specific Diagnostics announces discovery of a CRE signature in E. coli. growing in culture, to be presented at ECCMID global summit in April

Specific Diagnostics, which has developed a new microbiology diagnostic paradigm combining detection and identification (ID) of microorganisms growing in culture, announces today the discovery of a unique signature for deadly Carbapenem-resistant Enterobacteriaceae (CRE) strains of E. coli.  Specific will present its findings at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), on April 24, 2017, in Vienna, Austria.

February 28

Specific Diagnostics has been recognized as a National Institute of Allergy and Infectious Diseases (NIAID) Success Story, joining previous distinguished recipients including Illumina.

Specific Diagnostics, which has developed innovative paradigms for the detection, identification (ID) and antibiotic susceptibility testing (AST) of microorganisms growing in culture, announces today that the Company has been recognized as a “Success Story” by the National Institute of Allergy and Infectious Diseases (NIAID) Small Business Innovation Research (SBIR) program.